Johnson & Johnson Pauses Covid-19 Vaccine Trials Due to Sick Subject

By Peter Loftus

Johnson & Johnson said it has paused further dosing in all clinical trials of its experimental Covid-19 vaccine because a study volunteer had an unexplained illness.

The pause announced Monday affects all trials of J&J's vaccine, including a large Phase 3 trial that began in September and aimed to enroll up to 60,000 people in the U.S. and several other countries.

An independent data safety monitoring board is reviewing the study subject's illness, the company said. The company didn't immediately disclose more information about the illness.

This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern. Last month, AstraZeneca PLC paused clinical trials of an experimental Covid-19 vaccine after a participant in a U.K. study had an unexplained illness. The U.K. study resumed but a large U.S. study is still on hold.

Write to Peter Loftus at peter.loftus@wsj.com

(END) Dow Jones Newswires

October 12, 2020 22:26 ET (02:26 GMT)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024